MOUNTAIN VIEW, Calif.,
Jan. 4, 2011 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
company will present at the 29th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 11,
2011 at 8:00 a.m. PT in
San Francisco.
A live webcast of the presentation will be available on the
Investor Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay will also be available within 24
hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company
focused on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is developing
LEVADEX™ orally inhaled therapy for the potential treatment of
migraine and has reported positive results from the efficacy
portion of its Phase 3 trial of LEVADEX. In addition, MAP
Pharmaceuticals generates new pipeline opportunities by applying
its proprietary drug particle and inhalation technologies to
enhance the therapeutic benefits of proven drugs, while minimizing
risk by capitalizing on their known safety, efficacy and
commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
|
CONTACT:
|
|
|
Alex Bowie
|
|
|
WCG
|
|
|
(212) 301-7201
|
|
|
abowie@wcgworld.com
|
|
|
SOURCE MAP Pharmaceuticals, Inc.